Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

METHYLPHENIDATE IMPURITY C CRS (15 MG)

METHYLPHENIDATE IMPURITY C CRS (15 MG)

NA

DISCOVER
QUINAPRIL HYDROCHLORIDE CRS (30 MG)

QUINAPRIL HYDROCHLORIDE CRS (30 MG)

82586-55-8

DISCOVER
DOXYLAMINE FOR SYSTEM SUITABILITY CRS (110 MG)

DOXYLAMINE FOR SYSTEM SUITABILITY CRS (110 MG)

562-10-7

DISCOVER
FUROSEMIDE FOR PEAK IDENTIFICATION CRS (15 MG)

FUROSEMIDE FOR PEAK IDENTIFICATION CRS (15 MG)

54-31-9

DISCOVER
HYDROCHLOROTHIAZIDE FOR PEAK IDENTIFICATION CRS (15 MG)

HYDROCHLOROTHIAZIDE FOR PEAK IDENTIFICATION CRS (15 MG)

58-93-5

DISCOVER
SULFADIMIDINE FOR PEAK IDENTIFICATION CRS (50 MG)

SULFADIMIDINE FOR PEAK IDENTIFICATION CRS (50 MG)

57-68-1

DISCOVER
Cefoxitin for peak identification CRS, 15mg

Cefoxitin for peak identification CRS, 15mg

33564-30-6

DISCOVER
3-TRIMETHYLSILYL-1- PROPANESULFONIC ACID SODIUM SALT CRS (12

3-TRIMETHYLSILYL-1- PROPANESULFONIC ACID SODIUM SALT CRS (12

2039-96-5

DISCOVER
LOPINAVIR CRS (170 MG)

LOPINAVIR CRS (170 MG)

192725-17-0

DISCOVER
NEVIRAPINE HEMIHYDRATE CRS (15 MG)

NEVIRAPINE HEMIHYDRATE CRS (15 MG)

220988-26-1

DISCOVER
COIX SEED HRS (1300 MG)

COIX SEED HRS (1300 MG)

NA

DISCOVER
ORIENTVINE STEM HRS (600 MG)

ORIENTVINE STEM HRS (600 MG)

115-53-7

DISCOVER